We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Among the companies with shares expected to actively trade in Monday's session are DSW Inc. (DSW), Infinity Pharmaceuticals Inc. (INFI) and Steel Dynamics Inc. (STLD. Shoe retailer DSW projected...
Among the companies with shares expected to actively trade in Monday's session are Steel Dynamics Inc. (STLD) and K-V Pharmaceuticals Co. (KVA, KVB) Steel Dynamics forecast second-quarter earnings...
Glancy Binkow & Goldberg LLP announces that all persons or entities who purchased the securities of K-V Pharmaceutical Company (“K-V Pharmaceutical” or the “Company”...
Law Offices of Howard G. Smith, representing investors of K-V Pharmaceutical Company (“K-V" or the “Company”) (NYSE:KV-A) (NYSE:KV-B), has filed a class action lawsuit in the...
Notice is hereby given that Glancy Binkow & Goldberg LLP has filed a class action lawsuit in the United States District Court for the Eastern District of Missouri on behalf of a...
Faruqi & Faruqi, LLP, a national law firm concentrating on investor rights, consumer rights and enforcement of federal antitrust laws, is investigating potential wrongdoing at...
Former United States Securities and Exchange Commission attorney Willie Briscoe, founder of The Briscoe Law Firm, PLLC, and the securities litigation firm of Powers Taylor...
Law Offices of Howard G. Smith announces that a class action lawsuit has been filed on behalf of purchasers of the common stock of K-V Pharmaceutical Company (“K-V...
Zeldes & Haeggquist, LLP, a shareholder and consumer rights litigation firm, has commenced an investigation into possible violations of the federal securities laws by K-V...
K-V Pharmaceutical Company Announces Filing of Fiscal 2011 Form 10-K and Schedules Investor Conference Call PR Newswire ST. LOUIS, June 13, 2011 ST. LOUIS, June 13, 2011 /PRNewswire/ -- K-V...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
156 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
260 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions